AstraZeneca plc shared on Thursday that in the third quarter of fiscal 2023 its total revenue grew 5% year over year to reach $11.5 billion. On an annual basis, core earnings per share saw a rise of 4%, standing at $1.73, while operating profit surged 58% to $1.9 billion.
In the nine months ending September 30, compared to the same timeframe a year ago, total revenue increased 2% to $33.8 billion, diluted earnings per share skyrocketed 109% to $3.20 and operating profit soared %155 to $6.9 billion.
"Our company continued its strong growth trajectory in the third quarter ... Given the momentum in the year to date we have increased our full-year guidance for Total Revenue excluding COVID medicines as well as for Core EPS," CEO Pascal Soriot said.